Asian Spectator


The Times

.

LANDMARK’s ‘Destination CENTRAL’ Opens an Inspiring New Chapter for the Festive Season in Hong Kong

Heightening the Global Momentum of Louis Vuitton’s Monumental Façade and Welcoming the Arrival of “Christmas at The Gloucester Hotel”HONG KONG SAR – Media OutReach News...

Aliplast and NextChem signed an agreement for plastics recycling

ROME, Oct. 30, 2020 /PRNewswire-AsiaNet/ -- Maire Tecnimont S. P. A. and Hera Group announce that Aliplast, Hera Group's company for the collection, recycling and conversion of plastics, and...

Qashier Launches QashierGM, an AI General Manager That Works With the Whole Team

QashierGM works from each merchant's own sales, payouts and menu, and gets routine work done with the owner's approval. With Crew, Qashier's new team chat, anyone on the team can tag @GM to ...

Gowan Company Announces Acquisition of Two New Active Ingredie...

HARPENDEN, England, Dec. 3, 2019 /PRNewswire-AsiaNet/ -- --Company Expanding its Global Fungicide Portfolio Gowan Crop Protection Limited, an affiliate of Gowan Company, L.L.C., announced to...

Alma, A Sisram Medical Company, Launches Breakthrough ClearSki...

NURNBERG, Germany, Jan. 30, 2020 /PRNewswire-AsiaNet/ -- Alma, one of the top five global leaders of energy-based medical and aesthetics solutions, today announced launch of ClearSkin PRO, a...

Blockchain Used to Sell Real Estate for the First Time in the EU

PALO ALTO, California, Oct. 9, 2018/PRNewswire-AsiaNet/ -- - Propy Completed First Blockchain Property Transfer in EU MarketPropy, the global real estate platform, today announced the first ...

The Global Group: Proud Sponsor of Argentine Artist Carolina Kollmann’s Exhibition of Chinese Physiology 3D

HONG KONG, CHINA - Media OutReach - 7 November 2018 - International venture capital and angel investment firm the Global Group proudly presents Chinese Physiology 3D by Argent...

NTT DOCOMO and JR EAST Verify Stable 5G Communication aboard ALFA-X Shinkansen Test Train Running at 360km/h

TOKYO, Jan 29, 2021 - (JCN Newswire) - NTT DOCOMO, INC. and East Japan Railway Company (JR East) jointly announced that they have verified the stable operation of important 5G communication...

DENSO, Others Establish Social Cooperation Program at The University of Tokyo to Spur, Mobility Innovations, Meet United Nations' Sustainable Development Goals

TOKYO, Dec 2, 2020 - (JCN Newswire) - 1. Overview of the programFig. 1 SDGs to be achieved through the programFig. 2 Example of a system to be developed in the social cooperation programFig...

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

TOKYO, Mar 26, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).

This application is based on data from a multicenter, open-label, single-arm Phase II clinical study (study 205) conducted in Japan for patients with relapsed or refractory CTCL or PTCL to evaluate the efficacy and safety of this agent.

This study achieved the primary endpoint and exceeded a predetermined threshold with statistical significance: the objective response rate (ORR) of CTCL and PTCL patients in total (n=36) was 36.1% (95% confidence interval (CI): 20.8-53.8). The ORRs of each subtype were 31.6% (95% CI:12.6-56.6) for CTCL (n=19) and 41.2% (95%CI: 18.4-67.1) for PTCL (n=17).

The five most frequent adverse events observed in this study were increased aspartate aminotransferase (AST) (89.2%), increased alanine aminotransferase (ALT) (86.5%), hypoalbuminaemia (70.3%), lymphopenia (70.3%), and pyrexia (51.4%).

Denileukin diftitox (genetic recombinant) is a fusion protein of the receptor-binding portion of interleukin-2 (IL-2) and diphtheria toxin that specifically binds to the IL-2 receptor on the surface of tumoral lymphocyte. The antitumor effect of denileukin diftitox depends on the intracellular delivery of diphtheria toxin which inhibits protein synthesis and induces cell death. The agent has been evaluated as a drug with high medical need by the "Study Group for Unapproved Drugs/Off-Label Drugs for High Medical Needs"(1), and Eisai has been requested to develop it by the Ministry of Health, Labour and Welfare.

Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

(1) The Study Group set up within the Ministry of Health, Labour and Welfare with the purpose of contributing to enhancing the development of drugs and indications that have not been approved in Japan (unapproved drugs/off-label drugs) by pharmaceutical companies. In addition to evaluating the medical needs of unapproved drugs/off-label drugs, their responsibilities include evaluating the applicability of the drug to an Application with Public Knowledge, and the adequacy of additional clinical studies that need to be conducted for filing applications for approval, and so on.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegalzlibraryzlibraryuk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet girişStreamEastStreamEastjojobetcialis 20 mg fiyat